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Radiotherapy and chemotherapy are widespread clinical modalities for cancer treatment.
Among other biological inﬂuences, hypoxia is a main factor limiting the efﬁcacy of radiother-
apy, primarily because oxygen is involved in the stabilization of the DNA damage caused by
ionizing radiations. Radiobiological hypoxia is found in regions of rodent and human tumors
with a tissue oxygenation level below 10mmHg at which tumor cells become increasingly
resistant to radiation damage. Since hypoxic tumor cells remain clonogenic, their resis-
tance to the treatment strongly inﬂuences the therapeutic outcome of radiotherapy.There
is therefore an urgent need to identify adjuvant treatment modalities aimed to increase
tumor pO2 at the time of radiotherapy. Since tumor hypoxia fundamentally results from
an imbalance between oxygen delivery by poorly efﬁcient blood vessels and oxygen con-
sumption by tumor cellswith highmetabolic activities, two promising approaches are those
targeting vascular reactivity and tumor cell respiration.This review summarizes the current
knowledge about the development and use of tumor-selective vasodilators, inhibitors of
tumor cell respiration, and drugs and treatments combining both activities in the context of
tumor sensitization to X-ray radiotherapy.Tumor-selective vasodilation may also be used to
improve the delivery of circulating anticancer agents to tumors. Imaging tumor perfusion
and oxygenation is of importance not only for the development and validation of such com-
bination treatments, but also to determine which patients could beneﬁt from the therapy.
Numerous techniques have been developed in the preclinical setting. Hence, this review
also brieﬂy describes both magnetic resonance and non-magnetic resonance in vivo meth-
ods and compares them in terms of sensitivity, quantitative or semi-quantitative properties,
temporal, and spatial resolutions, as well as translational aspects.
Keywords: hypoxia, tumor vasculature, vasodilation, oxygen consumption, radiotherapy, chemotherapy, provascu-
lar anticancer therapy, tumor imaging
INTRODUCTION
Hypoxia, a partial pressure of oxygen (pO2) below physiological
needs, is a limiting factor affecting the efﬁciency of radiotherapy.
Indeed, the reaction of reactive oxygen species (ROS, produced
by water radiolysis) with DNA is readily reversible unless oxy-
gen stabilizes the DNA lesion. While normal tissue oxygenation
is around 40mmHg, both rodent and human tumors possess
regions of tissue oxygenation below 10mmHg, at which tumor
cells become increasingly resistant to radiation damage (radiobio-
logical hypoxia;Gray et al., 1953). Because of this so-called“oxygen
enhancement effect” (Figure 1), the radiation dose required to
achieve the same biologic effect is about three times higher in the
absence of oxygen than in the presence of normal levels of oxygen
(Gray et al., 1953; Horsman and van der Kogel, 2009). Hypoxic
tumor cells, which are therefore more resistant to radiotherapy
than well oxygenated ones, remain clonogenic, and contribute to
1This paper was originally published as “Jordan, B. F., and Sonveaux, P. (2011).
Targeting tumor perfusion and oxygenation modulates hypoxia and cancer sensi-
tivity to radiotherapy and systemic therapies” in Advances in Cancer Therapy, ed. H.
Gali-Muhtasib (Rijeka: Intech), 289–312.
the therapeutic outcome of fractionated radiotherapy (Rojas et al.,
1992).
Tumor hypoxia results from the imbalance between oxygen
delivery by poorly efﬁcient blood vessels and oxygen consumption
by tumor cells with high metabolic activities. On the one hand,
oxygen delivery is impaired by structural abnormalities present in
the tumor vasculature (Munn, 2003). They include caliber varia-
tions with dilated and narrowed single branches of tumor vessels,
non-hierarchical vascular networks, disturbed precapillary archi-
tecture, and incomplete vascular walls. These structural abnor-
malities cause numerous functional impairments, i.e., increased
transcapillary permeability, increased vascular permeability, inter-
stitial hypertension, and increased ﬂow resistance (Boucher et al.,
1996; McDonald and Baluk, 2002). It is however important to
note that, although hastily formed immature tumor microvessels
lack smooth muscle layer(s) and are therefore unable to provide
autoregulation, it is not uncommon to ﬁnd mature blood vessels
with smooth muscle layers and neural junctions inside slow-
growing tumors (e.g., most human tumors; Feron, 2004). On the
other hand, the altered tumor cell metabolism with elevated meta-
bolic rates also contributes to the occurrence of hypoxic regions
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FIGURE 1 |The oxygen enhancement effect in radiotherapy. In
biological tissues, irradiation primarily induces water ionization and
destabilization, leading to the formation of reactive radical species (A).
These species then react with neighboring molecules to yield reactive
oxygen species (ROS) (B), among which the hydroxyl radical is believed to
be the most cytotoxic. When generated in the proximity of DNA, hydroxyl
radicals and, to a lesser extent, other less energetic species attack DNA
(C). The resulting formation of a DNA radical is readily reversible. However,
in the presence of oxygen, DNA damage can be stabilized through
oxidation of DNA radicals, eventually leading to the formation of DNA
peroxides (D). In oncology, oxygen-dependent DNA damage ﬁxation is
known as the “oxygen enhancing effect” of radiotherapy.
in tumors and further causes extracellular acidiﬁcation. Tumor
hypoxia occurs in two ways: chronic hypoxia (or diffusion-limited
hypoxia), and acute hypoxia (or perfusion-limited or ﬂuctuating
hypoxia; Figure 2). Chronic hypoxia has classically been thought
to result from long diffusion distances between tumor vessels
as the consequence of the more rapid expansion of tumor cells
than that of the supporting vasculature (Vaupel et al., 1989). It
is now well established that steep longitudinal gradients of pO2
along the vascular tree, as opposed to radial diffusion of oxy-
gen, can largely contribute to deﬁciencies in tumor oxygen supply
(Dewhirst et al., 1999). The origin of acute hypoxia in tumors
is not ﬁrmly established. The commonly held view has been
that acute hypoxia results primarily from vascular stasis, which
stems from one of three causes: (1) vascular collapse in regions
of high tumor interstitial pressure, (2) vessel plugging by leuko-
cytes, and (3) impingement of tumor cells on the vascular lumen.
It has been demonstrated that temporal instability in tumor red
blood cell ﬂux could lead to transient hypoxia (Kimura et al.,
1996) and Dewhirst linked temporal changes in microvessel red
blood cell ﬂux to changes in the oxygen content in the same vessel
(Dewhirst et al., 1996). Factors that may contribute to ﬂow ﬂuctu-
ations include arteriolar vasomotion and rapid vascular modeling
(Dewhirst et al., 1996;Patan et al., 1996;Baudelet et al., 2004,2006).
More recent studies indicate a widespread presence of ﬂuctuating
hypoxia in solid tumors (Cardenas-Navia et al., 2008).
The effect of tumor hypoxia on the response to treatment by
ionizing radiation has been demonstrated in a multitude of exper-
imental studies. In a series of clinical studies in the early nineties,
Vaupel and others showed deﬁnitively that measurements of pO2
by polarographic microelectrodes provided useful criteria for pre-
dicting the response of tumors to radiation therapy (Gatenby et al.,
1988; Hockel et al., 1993; Okunieff et al., 1993; Stone et al., 1993;
Thomas et al., 1994). These results stimulated considerable efforts
in deﬁning and evaluating therapeutic approaches designed to
overcome tumor hypoxia as source of resistance (Horsman and
van der Kogel, 2009). A particular area under focus is thus to
combine radiotherapy with treatments that increase tumor pO2.
Other approaches consist to chemically radiosensitize hypoxic
cells or alternatively to exploit hypoxia as a mean to selectively
kill the resistant population of hypoxic cells. Before the advent
of imaging methods able to provide non-invasively oxygen esti-
mation, animal, and clinical studies were generally designed to
evaluate the effect of a given treatment on tumor pO2 as mea-
sured by Eppendorf or histologicalmarkers of tumor hypoxia. The
clinical end points were generally locoregional control and sur-
vival. Modiﬁers of oxygen delivery tested in clinical trials included
hyperbaric oxygen therapy (HBO), oxygen and carbogen breath-
ing. Hypoxic cell radiosensitizers (possessing a selective toxicity
for the radioresistant hypoxic cells) tested in clinical trials included
metronidazole, misonidazole, nimorazole, and tirapazamine. In a
systematic review, Overgaard (2007) identiﬁed 10,108 patients in
86 randomized trials designed tomodify tumorhypoxia in patients
treated with curative attempted primary radiation therapy alone.
Overall modiﬁcation of tumor hypoxia signiﬁcantly improved the
effect of radiotherapy for the outcome of locoregional control and
with an associated signiﬁcant overall survival beneﬁt. No signif-
icant inﬂuence was found on the incidence of distant metastases
or on the risk of radiation-related complications. From this meta-
analysis, the authors concluded in 2007 that “Ample data exist to
support a high level of evidence for the beneﬁt of hypoxic mod-
iﬁcation. However, hypoxic modiﬁcation still has no impact on
general clinical practice.”
Currently, the most advanced therapeutic interventions used in
the clinic to target tumor hypoxia are either the DAHANCA (Dan-
ish head and neck cancer) trial, the application of the ARCON
(Accelerated radiotherapy, carbogen, and nicotinamide) protocol,
and phase III studies with Tirapazamine. In the DAHANCA phase
III study, nimorazole has been used as hypoxic radiosensitizer on
422 patients, and it was shown that this compound improves the
effect of radiotherapeutic management in head and neck cancer
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FIGURE 2 |Tumor hypoxia. Hypoxia in tumors results from a mismatch
between the oxygen supply by poorly efﬁcient blood vessels and oxygen
consumption by metabolically overactive tumor cells. This simpliﬁed
cartoon depicts two main forms of hypoxia. Diffusion-limited hypoxia
refers to a gradient of oxygen deprivation from the nearest perfused blood
vessels toward tumor cells at increasing distances from this vessel. It
originates from high-rate of oxygen extraction though layers of cells within
a loosened vascular network. Perfusion-limited hypoxia refers to oxygen
deprivation along the vascular tree from the tumor margin toward the
tumor core. Poor oxygen delivery has many causes in tumors, including
high-rate of oxygen extraction at the tumor margin, decreased red blood
cell deformability, and stacking, increased blood viscosity due to water
extraction, vascular disorganization, and angiogenesis. Arrows represent
the blood ﬂow.
(Overgaard et al., 1998). Since these results, nimorazole adminis-
tration became part of the standard irradiation protocol for Head
and Neck cancer in Denmark. However, these ﬁndings have had
no impact on general clinical practice except for Denmark because
earlier generations of these agents induced rather severe periph-
eral neuropathy and because nearly all of the individual phase
III trials yielded negative or inconclusive results (Ang, 2010). The
ARCONprotocol consists in the combination of accelerated radio-
therapy to overcome tumor cell proliferation, carbogen breathing
to overcome diffusion-limited hypoxia, and nicotinamide to mini-
mize capillary bed shutdown and thereby reduce perfusion-related
acute hypoxia. Phase I and II clinical trials have shown the feasibil-
ity and tolerability of the treatment and have produced promising
results in term of tumor control, in particular in cancer of the head
and neck and bladder (Kaanders et al., 2002).A large improvement
in survival was demonstrated using this approach during radio-
therapy for bladder cancer. The randomized multicentre phase III
trial, designed and coordinated at Mount Vernon Cancer Centre,
demonstrated a 13% beneﬁt in overall survival when radiother-
apy was combined with carbogen and nicotinamide compared to
radiotherapy alone (Hoskin et al., 2009). Results froma large phase
III trial launched to test this regimen will become available within
the next 2 years. Finally, Tirapazamine (TPZ) has attracted interest
after preclinical studies showing that in addition to augmenting the
cytotoxicity of both radiation and cisplatin, this compound selec-
tively kills hypoxic cells (Rischin et al., 2001, 2005). Phase I and
II studies of the combination of TPZ with radiation and cisplatin
were performed on patients with locally advanced head and neck
carcinoma. On the basis of the phase II data, a large international
phase III trial was launched (Peters et al., 2010). Surprisingly, the
combination did not show any evidence of improvement in over-
all survival. Nevertheless, patients were not previously screened
for tumor hypoxia; the study was multicentric with some centers
enrolling fewer than ﬁve patients and a consequent decrease in
the quality of radiotherapy planning and delivery which can have
dramatic consequences on outcome (Ang, 2010).
This reviewwill explore two strategies to radiosensitizer tumors
to X-rays: to increase oxygen delivery by exploiting the reactivity
of mature tumor vessels (the so-called “provascular” approach)
and to decrease oxygen consumption by tumor cells. The goal of
the provascular approach is to temporarily increase tumor per-
fusion and oxygenation through pharmacological interventions.
Accordingly, radiotherapy could beneﬁt from tumor reoxygena-
tion whereas a decrease in interstitial pressure could facilitate
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tumor accessibility to circulating drugs. Alternatively, a second
approach is to decrease the oxygen consumption by tumor cells
since theoretical modeling studies demonstrated that reducing O2
consumption was far more efﬁcient at reducing tumor hypoxia
than increasing blood pO2 or ﬂow (Secomb et al., 1995). We
will also describe attempts to combine both approaches that
can be considered as complementary strategies. The evaluation
and validation of these adjuvant therapies (Table 1) require
imaging techniques capable of monitoring tumor perfusion and
oxygenation.
From the clinical analyses cited above, it also appeared that
the variation in the results among the trials reﬂects a considerable
heterogeneity among tumors and that patient individualization
would be mandatory for the success of such therapeutic approach.
There is therefore an essential need to predict individually the
presence of hypoxic regions in tumors. Based on individual tumor
characteristics and/or the ability to alleviate tumor hypoxia, it
will become possible to adapt the individual treatment either by
delivering optimal radiation doses into the resistant areas or by
delivering an associated treatment for potentiating the efﬁcacy
of radiation treatments. In the early nineties, invasive techniques
such as polarographic electrodes have been used in clinical stud-
ies to deﬁnitely establish the value of hypoxia as a predictive
marker of the response of tumors to irradiation. Although this
method was successful in demonstrating the central role played
by tumor hypoxia in the clinical response to radiation therapy,
it has never been used in standard clinical practice because of
its invasiveness and the difﬁculty to systematically carry out lon-
gitudinal studies in individual patients. Fortunately, it is now
possible to estimate tumor oxygenation by using minimally or
non-invasive techniques. This will be the purpose of the last part
of this review.
IMPROVING OXYGEN DELIVERY TO THE TUMOR: THE
PROVASCULAR APPROACH
Tumors are highly heterogeneous and this heterogeneity extends
to the tumor vasculature (see Introduction). Beside neovessels that
are the target of anti-angiogenic agents, human and rodent tumors
also contain blood vessels that are structurally mature (Mattson
et al., 1978; Peterson and Mattson, 1984). These vessels possess
the minimal contractile features (such as pericytes or vascular
smooth muscle cells) endowing them with vasocontractile prop-
erties. The intrinsic reactivity of tumor-feeding vessels modulates
oxygen delivery and the accessibility of circulating drugs to the
tumor. A selective and transient dilation of these vessels should
thus improve the tumor response to radiotherapy (which depends
on tumor oxygenation) and chemotherapy (which depends on
perfusion and on the vascular exchange area). We termed this
approach “provascular” to contrast with antivascular and anti-
angiogenic approaches that are destructive by nature (Sonveaux,
2008). The net effect of systemic vasodilation on tumor pO2 is
unpredictable because it primarily depends on the arrangement of
vessels (in series or in parallel) between the tumor and surround-
ing host tissues (Zlotecki et al., 1995). The key issue to resolve
is thus to identify tumor-selective vasodilators. Treatment opti-
mization would also require to monitor on individual bases the
tumor response to treatment, preferentially using early surrogate,
predictive, and non-invasive markers.
NITRIC OXIDE AND ENDOTHELIN-1 RELATED STRATEGIES
Physiologically, the vascular tone is determined by the balance
between nitric oxide (NO, a potent vasodilator) and endothelin-
1 (ET-1, a potent vasoconstrictor; Sonveaux and Feron, 2005).
A number of studies have explored the functionality and the
provascular exploitability of these two systems, as described below.
Table 1 | Pharmacological interventions able to radiosensitize tumors through selective vasodilation and/or decreased oxygen consumption by
tumor cells.
Treatment Tumor-selective
vasodilation
Decreased O2
consumption
Radiosensitization
to X-rays
Reference
NO donor drugs Yes Yes
(S-nitrosocaptopril)
Yes Sonveaux et al. (2009), Jordan et al. (2000), Segers et al.
(2010), Jordan et al. (2010), Jordan and Gallez (2010)
Nitrites Yes Yes Yes Frerart et al. (2008)
S-nitrosylated hemoglobin Potentially ND ND Sonveaux et al. (2005), Sonveaux et al. (2007b)
Insulin No Yes Yes Jordan et al. (2002), Jordan et al. (2006a)
X-rays Yes Yes Yes Sonveaux et al. (2009), Sonveaux et al. (2002),
Sonveaux et al. (2003, 2007a), Crokart et al. (2005b)
Endothelin-1 receptor A
inhibitors
Yes ND Yes Sonveaux et al. (2004), Martinive et al. (2006)
Anti-angiogenic agents
SU-5416 and ZD-6474
No Yes Yes Ansiaux et al. (2006, 2009)
Meta-iodobenzylguanidine ND Yes ND Biaglow et al. (1998)
Glucocorticoids No Yes Yes Crokart et al. (2007)
Non-steroidal
anti-inﬂammatory drugs
No Yes Yes Crokart et al. (2005a)
Mild hyperthermia Yes
(moderately)
Yes yes Lepock et al. (1987), Kelleher et al. (1995), Moon et al.
(2010), Brizel et al. (1996), Vujaskovic et al. (2003),
Jones et al. (2003, 2005)
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Exogenous and endogenous NO
NO was initially investigated for its vasodilatory activity and NO
donors were anticipated to improve the therapeutic efﬁcacy of
chemo- and radiotherapy upon combinational delivery (Sonveaux
et al., 2009). We ﬁrst considered the effect of the application of
exogenous NO on tumor hemodynamic parameters and radia-
tion response. This was performed by systemic administration
of NO donor compounds, including isosorbide dinitrate, (Jor-
dan et al., 2000) xanthinol nicotinate, (Segers et al., 2010), and
S-nitrosocaptopril (Jordan et al., 2010). The stimulation of the
production of endogenous NO was also achieved by administra-
tion of insulin (Jordan et al., 2002). All treatments resulted in
a transient acute improvement of experimental tumor oxygena-
tion with a consecutive increase in tumor radiosensitivity upon
sequential administrationof X-rays during the reoxygenationwin-
dow identiﬁed for each tumor model (Jordan et al., 2010). The
reoxygenation effect was shown to be due to an increase in tumor
blood ﬂow for Isosorbide Dinitrate, Xanthinol Nicotinate, and
S-nitrosocaptopril, using either dynamic contrast-enhanced mag-
netic resonance imaging (DCE-MRI), where the number of per-
fused voxels and/or Ktrans, Kep, or Vp parameters was increased
(see Dynamic Contrast-Enhanced MRI), or patent blue staining
(Jordan and Gallez, 2010). Importantly, for some co-treatments,
the increase in blood ﬂow occurred concomitantly with a decrease
in the rate of oxygen consumption by tumor cells. Inhibition
of tumor cell respiration is the main mechanism accounting for
insulin-induced tumor reoxygenation (see below).
Endogenous NO is produced by a series of enzymes collectively
termed NO-synthases (NOS). The endothelial isoform, eNOS,
is adapted for the local stimulation of vasodilation following a
response to stimuli that release calcium from intracellular stores
and promote a calcium-calmodulin-dependent release of eNOS
from its inhibitory complex with caveolin-1 (Cav-1; Arnold et al.,
1977; Michel et al., 1997). This mode of activation allows the tran-
sient production of micromolar amounts of NO responsible for
vasodilatation. Using myography, we showed that this system is
insensitive to classical eNOS stimulators (such as acetylcholine)
selectively in tumor arterioles, thus suggesting that strategies able
to restore eNOS activity would selectively target tumor vessels
(Sonveaux et al., 2002). Among different treatments, we have
found that ionizing radiations themselves were able to restore the
normal vasodilatory properties of tumor vessels. X-rays, through
the production of ROS, indeed induce an increase in eNOS expres-
sion concomitantly with a decrease in Cav-1 expression, which
removes a functional brake promoting eNOS activation (Sonveaux
et al., 2002, 2009). Irradiations further stimulate NO production
through the ROS-dependent activation of the PI3 kinase path-
way, a well described pathway supporting Akt-mediated eNOS
phosphorylation (on Ser1177, human sequence) and activation
(Sonveaux et al., 2003, 2007a). We documented that radiation-
induced vasodilation takes an active part in the antitumor effects
of X-rays by showing that eNOS inhibition between the ﬁrst and
second irradiation of a clinical regimen of fractionated radiother-
apy results in the total loss of the antitumor efﬁcacy of the second
dose, whereas eNOS inhibition before a single dose does not pre-
clude cytotoxic effects (Sonveaux et al., 2002). Active vasodilation
after each of the consecutive doses of fractionated radiotherapy
is associated with a window of tumor reoxygenation that offers
a scientiﬁc rationale for the clinical use of radiotherapy in its
fractionated mode.
S-nitrosylated hemoglobin and nitrites
A smart delivery of exogenous NO would help to resolve the Steal
Effect, a process through which systemic vasodilation may in fact
reduce tumor perfusion and oxygenation by redirecting blood to
normal blood vessels that are generally more sensitive to vasoac-
tive treatments and constitute a denser network (Zlotecki et al.,
1995). Using hemoglobin (Hb) is an interesting approach because
Hb is a physiological NO carrier (in the form of S-nitrosothiol)
poised to deliver NO selectively in hypoxic tissues such as tumors
(Sonveaux et al., 2005). NO delivery, indeed, is possible only after
the conformational change associated with Hb deoxygenation (Jia
et al., 1996; Stamler et al., 1997; McMahon et al., 2002). Using cell-
free human S-nitrosylated Hb (SNO-Hb) in rats, we documented
a transient increase in tumor perfusion, but only when SNO-Hb
was delivered in oxygenated blood (i.e., intra-arteriolar injection
or intravenous injection concomitantly with carbogen breathing;
Sonveaux et al., 2005). In deoxygenated blood, SNO-Hb would
otherwise readily deoxygenate and release NO at the site of deliv-
ery. While increased tumor perfusion at low dose SNO-Hb is pri-
marily attributable to central effects (i.e., baroreceptor inhibition),
SNO-Hb at higher doses could act as a tumor-selective vasodila-
tor and could therefore be used as a radiosensitizing treatment.
Inhalation of the NO donor gas ethyl nitrite, which promotes the
S-nitrosylation of intra-erythrocytic Hb in the lungs, could have
the same effects while minimizing toxic side effects associated with
the administration of naked Hb (Moya et al., 2002; Sonveaux et al.,
2007b).
While the use of SNO-Hb exploits hypoxia as a mean to selec-
tively deliver NO to tumors, one can also take advantage of the
low pH coupled to the high metabolic activities of many solid
tumors. Nitrites for example can be reduced to NO either by
enzymatic catalysis (nitrite reductase activities of xanthine oxi-
dase, eNOS, and Hb) or by non-enzymatic disproportionation,
and these processes are facilitated in an acidic microenviron-
ment (Zweier et al., 1999; Godber et al., 2000; Modin et al.,
2001; Angelo et al., 2006; Vanin et al., 2007). They have been
used clinically as an antidote for cyanide poisoning (Holland
and Kozlowski, 1986) which also indicates that they can be safely
administrated to humans. We therefore tested whether the low
pH of tumors (on average pH 6.7) could be exploited to gener-
ate NO from nitrites selectively in tumors. We observed ex vivo
that nitrite-induced vasodilation was more pronounced at pH
6.7 compared to pH 7.4 (Frerart et al., 2008). We also found
that the bioactivity of nitrites at low pH encompassed NO-
mediated inhibition of tumor cell respiration, which indicates
that the robust and transient increase in tumor pO2 after nitrite
delivery to mice is the result of the combination of vasoactive
and metabolic responses. When administered to reach a plasma
concentration of 100μM in mice, nitrites sensitized tumors to
radiotherapy (Frerart et al., 2008). Further clinical applications
are however confronted to ﬁnancial issues: clinical trials are now
warranted whereas nitrites or their use in cancer therapy can not
be patented.
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Endothelin-1 inhibitors
Endothelin-1 (ET-1) is a strong vasoconstrictor and an autocrine
growth factor produced by tumor cells (Shichiri et al., 1991;
Haynes and Webb, 1994). It has a key role in the accommodation
of vasoactive blood vessels to variations in intraluminal pressure:
ET-1 mediates the myogenic tone, a vasoconstriction that buffers
perfusion changes when the blood pressure increases (Huang and
Koller, 1997). In tumors, the constant exposure arterioles to ET-1
results in an increased myogenic tone that can be detected ex vivo
(Sonveaux et al., 2004).We reasoned that it constituted a reserve for
vasorelaxation that could be exploited to sensitize tumors to radio-
and chemotherapy. ET-1 induces vasoconstriction when binding
to ETA receptors expressed by contractile vascular cells (Maguire
and Davenport, 1995). Using the ETA antagonist BQ123, we
observed ex vivo a vasodilation selectively in tumor vessels (com-
pared to size-matched vessels from non-malignant tissues) that
translated in vivo into increased tumor perfusion and oxygenation
(Sonveaux et al., 2004). Both responses were tumor-selective and
transient. BQ123 as a pretreatment therefore improved the anti-
tumor effects of X-ray radiotherapy and cyclophosphamide (after
systemic delivery; Sonveaux et al., 2004; Martinive et al., 2006).
NORMALIZATION EFFECT OF ANTI-ANGIOGENIC AGENTS
Given that anti-angiogenic agents will likely be combined with
radiation therapy, it is critical to understand alterations in tumor
oxygenation and perfusion, as well as to deﬁne optimal time points
for the delivery of radiation. Our group previously studied the
modiﬁcations in the tumor environment early after treatment
with the anti-angiogenic agent thalidomide, with a special focus
on a possible normalization of the tumor vasculature (Jain, 2001;
Tong et al., 2004) that could be beneﬁcial for radiotherapy. Our
results showed an increase in tumor pO2 during the ﬁrst 2 days of
thalidomide treatment, which was likely the result of the ability
of thalidomide to modify tumor microenvironmental parameters
such as the vascular supply and tumor perfusion, as shown by
DCE-MRI (see Dynamic Contrast-Enhanced MRI) and histolog-
ical analysis using the endothelial marker CD31 (Ansiaux et al.,
2005). Indeed, the histological analysis revealed profound mod-
iﬁcations in the vascular supply: a reduction in the number of
tumor microvessels after thalidomide treatment together with a
dilation of the remaining vessels with no decrease in the tumor
vascular density. The perfusion measured by DCE-MRI showed
an increased plasma volume fraction (see Dynamic Contrast-
Enhanced MRI), which could be explained by the shift to larger
blood vessel diameters as observed in histology analysis, perhaps
due to compensation for the loss of small vessels. Interestingly,
similar observations were not obtained using more speciﬁc anti-
angiogenic agents such as SU-5416 or ZD-6474 (Ansiaux et al.,
2006, 2009). For these compounds, tumor reoxygenation was
rather due to a decrease in the rate of oxygen consumption by
tumor cell and no normalization effect was observed in the tumor
models under study (see below). We hypothesized that speciﬁc
inhibition of vascular endothelial growth factor (VEGF) signaling
viaVEGFR2 by SU-5416 or ZD-6474 may have been compensated
by another angiogenic pathway such as basic ﬁbroblast growth fac-
tor (bFGF), platelet-derived growth factor (PDGF), transforming
growth factor (TGF)-β, or Tie-2 signaling; (Stratmann et al., 1998;
Folkman et al., 2001) contrary to thalidomidewhich acts on differ-
ent angiogenic pathways. It is nevertheless important to note that
these ﬁndings are speciﬁc to the tumor models under study, since
ZD-6474 was described earlier to be able to decrease both ﬂow
and permeability in human colon tumors (Bradley et al., 2008)
and was able to induce transient normalization of the vasculature
in gliomas (Claes et al., 2008).
DECREASING OXYGEN CONSUMPTION BY TUMOR CELLS
Tumor oxygenation is a matter of supply and demand. Whereas
the provascular strategy intends to improve oxygen supply, sev-
eral strategies are aimed at decreasing oxygen consumption by
tumor cells rendering molecular O2 available for the stabilization
of radiation-induced DNA damage. Indeed, theoretical model-
ing studies demonstrated that reducing O2 consumption could be
more efﬁcient at reducing tumor hypoxia than increasing blood
pO2 or ﬂow (Secomb et al., 1995). Two main targets can be con-
sidered for inhibiting oxygen consumption: (i) direct interference
with the mitochondrial respiratory chain (at different levels), and
(ii) modulation of the redox status to change the mitochondrial
membrane potential (Pilkington et al., 2008) the ﬁnal aim being a
subsequent increase in tumorpO2 and enhancement of the efﬁcacy
of radiotherapy.
In contrast to provascular strategies, Laser Doppler ﬂowmetry,
DCE-MRI and electron paramagnetic resonance (EPR) oximetry
have revealed that the radiosensitizing effects of these treatments
are primarily caused by a decrease in the rate of oxygen con-
sumption by tumor cells, thus allowing oxygen to be redirected
from a metabolic fate to the stabilization of DNA lesions. Indeed,
apart from NO donors, all the treatments described below did
not show any signiﬁcant increase in tumor blood ﬂow concomi-
tant to the increase in tumor oxygenation. Some of them even
showed a decrease in tumor blood ﬂow that was counteracted by
the dramatic decrease in oxygen consumption by tumor cells (i.e.,
insulin and NS-398). In addition, regarding NO-mediated treat-
ments, our models showed that the radiotherapeutic response not
only depended on the tumor pO2 but also on the net level of NO
achieved at the time of irradiation,NO itself being able to stabilize
irradiation-induced DNA lesions in vivo (Jordan et al., 2004).
The ﬁrst drug that was described to inhibit oxygen consump-
tion in tumors was meta-iodobenzylguanidine (MIBG), which
causes an inhibition of the mitochondrial site I electron transfer,
inhibition of NAD(P)H oxidation, and is described to alter tumor
glycolysis by inhibiting oxygen consumption (Biaglow et al., 1998).
We consecutively focused on different innovative treatments that
may alter oxygen consumption by tumor cells, as listed below.
INSULIN
This hormone was known to increase blood ﬂow in human skele-
tal muscle and was postulated to be an important modulator of
tumor oxygenation (Jordan et al., 2002). Indeed, we showed that
insulin had a profound effect on tumor oxygenation that was
not due to an increase in tumor blood ﬂow but to a decrease
in tumor cell oxygen consumption. The increase in tumor oxy-
genation resulted in an important enhancement in the sensitivity
of tumors to irradiation. The likely scenario involves a stimula-
tion of eNOS and a consequent increase in NO release. As NO
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regulates mitochondrial respiration by virtue of reversible inter-
actions with cytochrome c oxidase (complex IV), an increase in
NO release consequently decreased cell respiration (Jordan et al.,
2002). A preclinical study conﬁrmed the dose-dependant increase
in tumor oxygenation and radiation sensitivity by insulin, without
any increase in the radiation toxicity for normal tissues (Jordan
et al., 2006a).
GLUCOCORTICOIDS
Earlier work had demonstrated that the administration of cor-
tisone to rats resulted in both the inhibition of oxygen con-
sumption and the uncoupling of oxidative phosphorylation
in liver mitochondria (Kimberg et al., 1968). Glucocorticoids
seemed to decrease the cytochrome c oxidase (complex IV)
activity of isolated rat kidney mitochondria by a direct mech-
anism (Simon et al., 1998). Our group showed an important
increase in tumor oxygenation induced by an effect on oxy-
gen consumption. Decreased oxygen consumption could be
explained by the capacity of glucocorticoids to inhibit cytochrome
c oxidase of the mitochondrial respiratory chain. The result
of this increase in tumor oxygenation was an improvement
of the radiation efﬁcacy by a factor of 1.7 (Crokart et al.,
2007).
ANTI-INFLAMMATORY DRUGS
Several reports indicated that many non-steroidal anti-
inﬂammatory drugs (NSAIDs) uncouple mitochondrial oxidative
phosphorylation with important consequences on cell oxygen
consumption. However, it was suggested that the response was
dependent on the dose as well as on the type of NSAIDs. For the
ﬁrst time, our group reported that the administration of NSAIDs
induced a dramatic increase in tumor oxygenation explained by
reduced oxygen consumption. An increase in the tumor response
was observed when the irradiation was applied at the time of
maximal reoxygenation (Crokart et al., 2005a).
THYROID HORMONES
Chronic alteration in the thyroid status has been shown to affect
mitochondrial oxygen consumption in skeletal muscle (Gredilla
et al., 2001). Also, studies have demonstrated that hypothyroidism
slows down the neoplastic process, whereas administration of a
thyroid hormone preparation restores tumor growth rates (Shoe-
maker and Dagher, 1979; Mishkin et al., 1981; Theodossiou et al.,
1999). In humans, several case reports have indicated a pro-
longed survival in the presence of hypothyroidism (Hercbergs
and Leith, 1993; Cristofanilli et al., 2005). Moreover, a decrease
in the thyroid function may also serve to favorably inﬂuence the
response to treatment. Finally, patients presented an enhanced
response rate to chemotherapy and survived signiﬁcantly longer
under hypothyroidism (Hercbergs et al., 2003).Our group recently
demonstrated that the thyroid status is associated with a signiﬁ-
cant change in tumor radiosensitivity since the regrowth delay
was increased in hypothyroid mice compared to euthyroid mice.
Mechanistically, we demonstrated that the higher level of tumor
oxygenation in hypothyroid mice results from a signiﬁcant reduc-
tion in the oxygen consumption rate of tumors (Jordan et al.,
2007).
NO DONORS
We recently tested whether S-nitrosocaptopril, a molecule com-
bining a NO donor and an angiotensin converting enzyme
inhibitor (ACE inhibitor), could temporarily improve the hemo-
dynamic status of experimental tumors. We identiﬁed a time
window during which tumor oxygenation was improved, as a
result of a combined effect on tumor blood ﬂow and oxygen con-
sumption. Consequently, the administration of S-nitrosocaptopril
contributed to the increase in efﬁcacy of radiation therapy, an
effect that was not observed with captopril alone (Jordan et al.,
2010).
ANTI-ANGIOGENIC AGENTS
As stated earlier, two anti-angiogenic agents, SU-5416 and ZD-
6474, have also been identiﬁed as potent inhibitors of oxygen
consumption (Ansiaux et al., 2006, 2009). Our major ﬁndings
regarding those speciﬁc anti-angiogenic agents were the follow-
ing: (a) SU-5416 and ZD-67474 both induce an increase in tumor
oxygenation at an early phase of treatment (after 2 days of daily
injections); (b) this tumor reoxygenation can be exploited to
increase the efﬁcacy of combined radiotherapy; (c) the mecha-
nism of increase in tumor oxygenation does not involve a “nor-
malization” of the tumor vasculature as described previously for
thalidomide in the same tumor model (Ansiaux et al., 2005) but
is consistent with the decrease in the rate of oxygen consumption
by the tumor cells. Indeed, at this early stage of the treatment,
no apparent remodeling of the tumor vasculature and no changes
in tumor perfusion and permeability parameters were observed,
using histological and DCE-MRI analysis, respectively. We how-
ever demonstrated a reduction in tumoroxygen consumption after
those treatments. The reduction factor in oxygen consumption
observed was sufﬁcient to abolish tumor hypoxia, as we reported
previously using the treatments listed above.
HYPERTHERMIA: COMBINING PROVASCULAR AND OXYGEN
CONSUMPTION EFFECTS IN A SINGLE TREATMENT
Hyperthermia is a potent adjuvant therapy with radiotherapy and
chemotherapy, and the perfect illustration of a strategy combin-
ing transient, local vasodilatation with the inhibition of tumor
cell respiration. The heat treatment consists of elevating the tem-
perature of tumors to a supra-physiological range of 40–45˚C
at which tumor reoxygenation occurs with limited skin toxicity.
Hyperthermia induces a graded response in tissues characterized
by decreased oxygen consumption at temperatures ≥40˚C, vasodi-
latation between 41 and 41.5˚C, and vascular damage above 42˚C.
Although direct tumor cell killing was demonstrated in vitro at
higher temperatures, long-term tumor control has never been
demonstrated using hyperthermia as the sole treatment modality.
Vasodilation only modestly contributes to tumor reoxygenation
at the low thermal doses. Increased pO2 rather primarily results
fromchanges in oxygen consumption in the target cells, and at least
two different processes have been identiﬁed to contribute to this
response. It is now well demonstrated that an important target of
heat is proteins among which enzymes of the respiratory chain are
more sensitive to heat inactivation/denaturation than glycolytic
enzymes (Lepock et al., 1987; Kelleher et al., 1995). But the inhi-
bition of mitochondrial respiration by heat lasts longer than the
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turnover time of respiratory enzymes, suggesting the existence
of an additional mechanism. Dewhirst in collaboration with our
team (Moon et al., 2010) recently demonstrated that mild hyper-
thermia activates the transcription factor hypoxia-inducible factor
1 (HIF-1) through an hypoxia-independent mechanism involv-
ing the sequential activation of Extracellular signal-Regulated
Kinases (ERK) by heat shock, ERK-induced upregulation of the
expression of the Nox1 subunit of NAD(P)H oxidase, increased
ROS production by NAD(P)H oxidase, ROS-induced HIF-1α pro-
tein stabilization, and, ultimately, HIF-1 activation. HIF-1 target
genes include most glycolytic enzymes and transporters as well
as major pro-angiogenic molecules such as VEGF. Among these
genes, we showed that pyruvate dehydrogenase kinase 1 (PDK1)
largely mediates the inhibition of mitochondrial respiration by
heat in tumor cells through inhibiting pyruvate dehydrogenase
(PDH), i.e., the enzyme coupling glycolysis to the tricarboxylic
acid (TCA) cycle (Moon et al., 2010). Furthermore, consistent
with the increase in VEGF expression that we also observed in
heat-treated tumors, we documented an increased vascular den-
sity in perfused tumor areas where oxygen is extracted from
the blood. Tumor reoxygenation by mild hyperthermia is thus
a multifaceted process involving the combination of decreased O2
consumption by tumor cells and increased O2 delivery by blood
vessels. This and the fact that reoxygenation occurs at thermal
doses lower than those inducing vascular damage justiﬁes the use
of mild hyperthermia as a combination treatment notably with
radiotherapy. Although several clinical trials have conﬁrmed that
combining heat and radiotherapy is indeed associated with bet-
ter patient treatment outcome (Brizel et al., 1996; Jones et al.,
2003, 2005; Vujaskovic et al., 2003) the future clinical develop-
ment of hyperthermia strongly relies on designing tools allowing
for homogeneous thermal dose distribution and improving imag-
ing techniques able to correlate thermal maps of tumors to the
clinical outcome of patients (Dewhirst et al., 2010).
NON-INVASIVE IMAGING OF TUMOR OXYGENATION AND
PERFUSION
The study of magnetic resonance (MR) markers over the past
decade has provided evidence that the tumor microenvironment
and hemodynamics play a major role in determining therapy out-
come. Therefore, the identiﬁcation of relevant non-invasive imag-
ing endpoints is of crucial importance in the management of can-
cer patients. Improvement of the therapeutic index was evidenced
in numerous preclinical studies that used multimodal imaging.
The impact of non-invasive imaging in oncology extends from
guiding preclinical development of targeted biomarkers and ther-
apeutic agents, to assisting in the diagnosis and staging of tumors
in the clinic, as well as monitoring the therapeutic response.
TUMOR OXYGENATION MEASUREMENTS
There is a critical need for developing dynamic, non-invasive
methods for direct oxygen mapping in the clinical practice.
Although hypoxia is recognized as a crucial issue in many dis-
orders and in treatment response, the lack of easy-to-use and
efﬁcient methods to quantify oxygen deprivation hampers further
pathophysiological understanding and restricts the clinical imple-
mentation of oxygen mapping techniques resulting in the absence
of gold standard for measuring hypoxia in the day-to-day practice
(Tatum et al., 2006). Below is a non-exhaustive review of the
most relevant non-invasive methods able to assess tumor hemo-
dynamic parameters. Methods to measure absolute pO2 mostly
encompass EPR oximetry and 19F relaxometry whereas indirect
methods include blood oxygen level dependent (BOLD) MRI,
Oxygen enhanced relaxation MRI, Oxygen enhanced longitudinal
relaxation MRI, and positron emission tomography (PET) tracers
retained in hypoxic regions. Of note, our group has also devel-
oped innovative methods to assess tumor oxygen consumption
in vitro and in vivo, which have been reviewed elsewhere (Jordan
and Gallez, 2011).
Electron paramagnetic resonance oximetry
Electron paramagnetic resonance is aMRmethod that detects only
species containing unpaired electrons (Gallez and Swartz, 2004).
One of the numerous applications of EPR is in vivo oximetry.
Molecular oxygen is a triplet radical that possesses two unpaired
electrons which are responsible for its paramagnetism. However,
EPR is not able to detect oxygen itself when dissolved in ﬂuids near
room temperature: in biological systems, the output signal lines are
so broadened as to be undetectable. Indirect methods exist. Most
of thesemethods rely on the paramagnetic properties of molecular
oxygen, which acts as an efﬁcient relaxer for other paramagnetic
species (Gallez et al., 2004). The enhancement of relaxation rates
scales linearly with the concentration of oxygen over a wide range
of oxygen tensions (typical data are shown in Figure 3). The lack
of detectable levels of endogenous paramagnetic species makes
it necessary to use exogenous paramagnetic materials. Variations
in pO2 of less than 1mmHg can be detected using particulate
materials. While EPR spectroscopy provides local measurements,
EPR imaging techniques provide spatially resolved measurements
of these materials. The spatial distribution of free radicals can be
performed utilizing magnetic ﬁeld gradients in a manner similar
to that of MRI. Spectral–spatial EPR imaging encodes both the
spatial distribution of the spin probe and the spectral informa-
tion, which allows the mapping of molecular oxygen (Kuppusamy
et al., 2003). For this purpose, the use of soluble EPR materials
such as trityl radicals is more convenient as they can diffuse in the
whole tissue.
Electron paramagnetic resonance oximetry was compared with
other methods that provide direct or indirect measurements of
tumor oxygenation: polarographic electrodes, the distribution
of nitroimidazoles, the BOLD effect in MRI, and pO2 record-
ings using OxyLite (reviewed in Gallez et al., 2004). Two major
challenges are now considered for moving this technology into
the clinic: (i) assuring biocompatibility of the oxygen sensors in
humans and (ii) modifying the instruments so that they can be
used for humans instead of small animals (Swartz et al., 2004).
19F relaxometry
19F NMR spectroscopy and imaging of perﬂuorocarbon (PFC)
emulsions (hydrocarbons with protons having been replaced with
ﬂuorine nuclei) has been extensively exploited to measure the oxy-
gen tension of biological systems in preclinical studies. The 19F
MR signal of the PFC is sensitive to the pO2 of the surround-
ing tumor tissue, and acts as an oximeter. The principle behind
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FIGURE 3 | Electron paramagnetic resonance oximetry.Typical
sets of EPR data are shown. (A) Effect of oxygen on the EPR spectra
of paramagnetic particulate materials: EPR spectra recorded in
nitrogen (narrow line) or in air (21% oxygen, larger linewidth). (B)
Typical calibration curve (linewidth as a function of the pO2) of a
charcoal (oxygen sensor probe) possessing a curvilinear response,
with a higher sensitivity to oxygen at low pO2. Adapted from Gallez
et al. (2004).
19F MR oximetry relies on the linear increase of the NMR spin
lattice relaxation rate R1 (=1/T 1) of PFC emulsions with increas-
ing oxygen tension (Mason et al., 1996). 19FMRoximetry provides
a sensitive measure of tissue oxygen tension and is a powerful
approach for monitoring tumor hypoxia. Several PFCs have been
used forNMRoximetry,but hexaﬂuorobenzene (HFB) is preferred
(Mason et al., 1996; Zhao et al., 2004) because it has a sixfold sym-
metry with a single 19F NMR resonance, and a low sensitivity to
temperature. Its spin lattice relaxation rate is highly sensitive to
pO2 and exhibits a linear relationship across the entire range of
tissue oxygenation.
Mason and colleagues have been successfully developing ﬂu-
orocarbon relaxometry using echo planar imaging for dynamic
oxygen mapping (FREDOM) MRI following direct intratumoral
injection of the oxygen reporter molecule HFB. Our group fur-
ther developed an MRI ﬂuorocarbon oximetry technique using
snapshot inversion recovery with an improved temporal resolu-
tion of 1.5min (vs. 6.5min for FREDOM; Jordan et al., 2009). Our
method therefore provides a rapid way to map tumor oxygenation
(typical maps are shown in Figure 4) and is particularly suitable to
monitor acute changes of pO2 in tumors, including spontaneous
ﬂuctuations (Jordan et al., 2009; Magat et al., 2010). The transla-
tion to the clinic is currently limited by the lack of development
of coils in the clinical setting, and the lack of characterization of
PFCs in humans.
Blood oxygen level dependent MRI
Functional MRI (fMRI) was ﬁrst developed as an indirect method
of imaging brain activity at high temporal resolution (Ogawa et al.,
1990). The relative decrease in deoxyhemoglobin concentration,
which has a paramagnetic effect, can be detected by MRI as a
weak transient rise in the T ∗2 weighted signal. This is the BOLD
contrast principle. Apart from its very large application in neu-
roscience, the use of BOLD contrast in tumors brought with it
new challenges of understanding and interpretation. Since then,
BOLD MRI has become a useful tool for addressing important
questions regarding the pathophysiology of tumors. However, it
has both advantages and disadvantages. One advantage of BOLD
MRI is that it is non-invasive and can be used to monitor real
time changes of tumor oxygenation during pharmacological treat-
ments or to monitor spontaneous ﬂuctuations in experimental
tumors (Baudelet and Gallez, 2002; Baudelet et al., 2004). It does
not require externally administered contrast medium or radioac-
tive isotopes, it can be repeated as necessary, and ﬂow dependence
can be decoupled. BOLD MRI, in combination with hypercapnia
and hyperoxia, is also an attractive method for assessing matu-
ration and the functional state of tumor blood vessels (Baudelet
et al., 2006). As for disadvantages, BOLD MRI is unfortunately a
non-quantitative method for monitoring tumor pO2. This is the
result of the extreme sensitivity of changes in R∗2 to the basal state
of tumor oxygenation and blood volume fraction. The intra and
intertumoral distribution of these parameters may be greatly het-
erogeneous, making it very difﬁcult to compare estimated pO2
changes between two regions or individuals. Even more problem-
atic is the fact that the change in R∗2 is not always indicative of the
change in pO2. Concomitant changes in blood volume, blood pH
and metabolic status can lead to smaller-than-expected or even
negative changes in R∗2 (Baudelet and Gallez, 2002). Similarly,
changes in oxygen consumption rate has been described to result
in a lack of change in R∗2 even though absolute pO2 is increased
(Jordan et al., 2006b).
Oxygen enhanced longitudinal relaxation MRI
An alternative MRI technique for evaluating change in tumor oxy-
genation using endogenous contrast relies in the increase of the
proton longitudinal relaxation rate (R1) of water containing oxy-
gen, due to the paramagnetic properties of oxygen. The measured
change in R1 is, in theory, proportional to the change in tissue
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FIGURE 4 | 19F-MRI oxygen mapping. Shown are typical oxygen maps
obtained using 19F-MRI with hexaﬂuorobenzene as the oxygen sensor in an
experimental tumor under air or carbogen (95% O2, 5% CO2) breathing
conditions. The corresponding histograms are shown, in which “n”
represents the number of voxels for a given oxygen concentration range.
Adapted from reference Jordan et al. (2009).
oxygen concentration (O’Connor et al., 2007, 2009). Studies have
indeed demonstrated that oxygen enhanced MRI produces mea-
surable signal changes in normal tissues in patients and is feasible
on conventional clinical scanners. Therefore, oxygen-induced
increase in R1 has the potential to provide non-invasive measure-
ments of change in tumor oxygen concentration, distinct from
BOLD imaging. Nevertheless, the technique still lacks in sensitiv-
ity and the measured delta R1 may include errors resulting from
changes independent of tissue oxygen content, such as alteration
in blood ﬂow or tissue H2O content (O’Connor et al., 2009).
Hypoxia assessed by positron emission tomography
18F labeled ﬂuoromisonidazole (18F-MISO) is probably the most
widely used PET imaging agent for hypoxia. 18F-MISO accumu-
lates in tissues by binding to intracellular macromolecules when
pO2<10mmHg.Retentionwithin tissues is dependent onnitrore-
ductase activity (that is, on the reduction status of a NO2 group
on the imidazole ring) and accumulation in hypoxic tissues over
a range of blood ﬂows has been observed (Tatum et al., 2006).
18F-MISO is only sensitive to the presence of hypoxia in viable
cells: 18F-MISO is not retained in necrosis because the electron
transport chain that reduces the nitroimidazole to a bioreductive
alkylating agent is no longer active (Padhani et al.,2007).Neverthe-
less, 18F-MISOPET is able tomonitor the changing hypoxia status
of lung tumors during radiotherapy (Koh et al., 1995). Studies in
sarcoma (Rajendran et al., 2003) and head and neck cancer (Rajen-
dran et al., 2006) have demonstrated a correlation of 18F-MISO
uptake with poor outcome to radiation and chemotherapy. Other
18F labeled nitroimidazoles are currently evaluated, including EF3
and ﬂuoroazomycin arabinoside (FAZA), for example (Tatum
et al., 2006).
TUMOR PERFUSION MEASUREMENTS
Microvascular parameters such as permeability and perfusion
are of particular interest in the context of the abnormal tumor
microvascular network. Useful imaging systems have been devel-
oped to monitor angiogenesis and the microvasculature in vivo,
including DCE-MRI, (Choyke et al., 2003) PET, and single photon
emission computed tomography (SPECT), CT, Doppler ultra-
sound, and optical imaging methods (see Jennings et al., 2008).
Dynamic contrast-enhanced MRI
Dynamic contrast-enhanced magnetic resonance imaging consists
in the acquisition of serial MR images before, during, and after the
administration of an intravenous contrast agent (CA) to produce
time series images that enable pixel-by-pixel analysis of contrast
kinetics within a tumor. Pharmacokinetic models provide a means
of summarizing contrast enhancement data in termsof parameters
that relate to the underlying vascular anatomy and physiology. As
described by Tofts et al. (1999) the essential features of a variety of
models are covered by the generalized kinetic model. Most meth-
ods of analyzing dynamic contrast-enhanced T 1-weighted data
acquired with low molecular contrast medium use a compart-
mental analysis to obtain some combination of the three principal
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parameters: the transfer constant Ktrans in min−1 (volume trans-
fer constant between blood plasma and extravascular extracellular
space, EES), the rate constant Kep inmin−1 (rate constant between
blood plasma and EES), and the volume of EES per unit volume of
tissue space, Vp (no unit). DCE-MRI has evolved from an exper-
imental technique to a clinically feasible adjunct procedure that
can be integrated into a standard morphologic imaging proto-
col. It does provide unique non-invasive functional information
on the properties of tumors related to microcirculation (distri-
bution volume, permeability, and perfusion). This information
can improve diagnostic characterization, the follow-up of ther-
apy, and tumor staging; and it provides tools to facilitate advanced
molecular imaging. Preclinical and clinical studies suggest that a
successful antivascular treatment results in a decrease in the rate
of enhancement along with a decreased amplitude and a slower
washout, and that poor response can result in persistent abnormal
enhancement (Gillies et al., 2002).
Positron emission tomography
Generally, PET measures of tumor perfusion have used (15O)-
labeled radiotracers. The so-called steady state method requires
inhalation of 15O-CO2 and the dynamic method requires an
intravenous bolus injection of 15O-H2O (Jennings et al., 2008). A
requirement for quantiﬁcation of perfusion using dynamic meth-
ods is an accurate determination of an arterial input function,
which can be obtained non-invasively in a purely arterial region
of interest, such as the aorta.
Computed tomography
In X-ray CT, the tissue contrast is based on variable attenuation
coefﬁcients of the object absorbing the X-rays. Hemodynamic
parameters may be extracted from dynamic changes in X-ray
attenuation caused by the intravenous injection of an iodinated
contract agent. Perfusion CT data can deliver quantitative hemo-
dynamic information, such as blood volume, blood ﬂow, perme-
ability surface-area product andmean transit time (MTT; Jennings
et al., 2008).
Doppler ultrasound
There are several different ultrasonic approaches designed speciﬁ-
cally to measure blood ﬂow including transit time, continuous-
wave Doppler, pulsed and color Doppler, and power Doppler
ﬂowmeters, requiring the use of microbubbles (ﬁlled with air, per-
ﬂuorocarbon, sulfur hexaﬂuoride, or nitrogen),which expand and
contract because of pressure from the acoustical transmit pulse,
and the primary mode of echogenicity is the impedance mis-
match between the microbubble–blood interface, making them
signiﬁcantly more echogenic than normal tissue. Typical parame-
ters that are estimated using Doppler ultrasound include: percent
intratumor CA uptake, enhancement timing and pattern, per-
cent blood volume fraction, red blood cell velocity, and perfusion;
depending on the type of study and tracer used (Jennings et al.,
2008).
CONCLUSION
Heterogeneities in blood ﬂow and oxygenation are key character-
istics of solid tumors and constitute a therapeutic challenge when
these tumors are treated with radiotherapy or systemic therapies.
Because oxygen stabilizes DNA lesions, tumors become increas-
ingly resistant to radiotherapy and to several forms of chemother-
apywhen the tumor pO2 decreases below a threshold of 10mmHg.
In the past decades, basic and preclinical researches have identiﬁed
several adjuvant treatments aimed at transiently increasing tumor
oxygenation at the time of radiotherapy. Their identiﬁcation was
based on an increasing understanding of the origins of tumor
hypoxia, which logically opened two main avenues: co-treatments
designed to (1) improve the oxygen supply from blood vessels at
the time of radiotherapy (with different strategies such as increas-
ing the O2 content of blood, inducing tumor-speciﬁc vasodila-
tion, or normalizing vascular structures), and (2) reduce the rate
of O2 consumption by tumor cells through metabolic interven-
tions. Theoreticalmodels nowvalidated preclinically have revealed
that the metabolic strategy has the highest impact on tumor
radiosensitivity, but the best opportunity still resides in treat-
ments combining both vascular and metabolic effects (Table 1), as
perfectly illustrated with hyperthermia. Most systemic anticancer
treatments are also confronted to the difﬁculty to reach a tar-
get often located at distance from blood vessels, thus indicating
that in this case increased tumor perfusion (i.e., decreased resis-
tance to ﬂow) could improve tumor bioavailability. NO donors,
ET-1 inhibitors, radiotherapy or heat as adjuvant provascular
treatments, or anti-angiogenic therapies and chemotherapy used
in a “vascular normalization” mode, have all demonstrated their
capacity to chemosensitize tumors in preclinical settings. Most
of the adjuvant treatments described here could theoretically be
exploited therapeutically by the off-label use of existing FDA-
approved drugs, but it has also become evident that a given tumor
in a given patient would respond differently than the tumor of
the patient next-door. It is therefore urgent to develop and imple-
ment in the clinics imaging techniques able not only to provide
predictive markers but also biological markers of the response to
such combinational interventions. The MR and PET techniques
that we reviewed here are among the most-sensitive non-invasive
techniques having proved their highly valuable power as to mea-
sure changes in tumor perfusion and oxygenation preclinically.
Current challenges include the FDA approval of exogenous tracers
and sensors when needed, scaling-up tools initially dedicated for
small laboratory animals and adapting imaging protocols to the
clinical situation, the transfer to the clinics of the expertise needed
for protocol design and data interpretation and, as importantly, a
careful consideration of societal cost issues.
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